RU2533116C2 - Оксииндольные производные, обладающие агонистической активностью в отношении мотилинового рецептора - Google Patents

Info

Publication number

RU2533116C2

RU2533116C2 RU2011139287/04A RU2011139287A RU2533116C2 RU 2533116 C2 RU2533116 C2 RU 2533116C2 RU 2011139287/04 A RU2011139287/04 A RU 2011139287/04A RU 2011139287 A RU2011139287 A RU 2011139287A RU 2533116 C2 RU2533116 C2 RU 2533116C2

Authority

RU

Russia

Prior art keywords

piperidin

dimethyl

oxoindolin

oxo

phenylbutan

Prior art date

2009-02-27

Links

• Espacenet
• Global Dossier
• Discuss

• 230000000694 effects Effects 0.000 title claims abstract description 29
• 108700040483 Motilin receptors Proteins 0.000 title claims abstract description 20
• 102000057413 Motilin receptors Human genes 0.000 title claims description 19
• 239000000556 agonist Substances 0.000 title claims description 17
• PTXVSDKCUJCCLC-UHFFFAOYSA-N 1-hydroxyindole Chemical class C1=CC=C2N(O)C=CC2=C1 PTXVSDKCUJCCLC-UHFFFAOYSA-N 0.000 title abstract 3
• -1 C-Calkyl Chemical group 0.000 claims abstract description 100
• 150000003839 salts Chemical class 0.000 claims abstract description 47
• 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 36
• 239000001257 hydrogen Substances 0.000 claims abstract description 36
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 24
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 21
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 19
• 229910052736 halogen Inorganic materials 0.000 claims abstract description 17
• 150000002367 halogens Chemical group 0.000 claims abstract description 17
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 16
• 239000003814 drug Substances 0.000 claims abstract description 16
• 150000002431 hydrogen Chemical class 0.000 claims abstract description 15
• 230000001404 mediated effect Effects 0.000 claims abstract description 15
• 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 14
• 125000000217 alkyl group Chemical group 0.000 claims abstract description 12
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 10
• 229910052799 carbon Inorganic materials 0.000 claims abstract description 10
• 229910052760 oxygen Inorganic materials 0.000 claims abstract description 10
• 239000001301 oxygen Substances 0.000 claims abstract description 10
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
• 125000004429 atom Chemical group 0.000 claims abstract description 6
• 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 6
• 125000002947 alkylene group Chemical group 0.000 claims abstract description 5
• 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 4
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract description 4
• 150000001875 compounds Chemical class 0.000 claims description 192
• 238000000034 method Methods 0.000 claims description 136
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
• 208000035475 disorder Diseases 0.000 claims description 20
• 239000002253 acid Substances 0.000 claims description 17
• 201000010099 disease Diseases 0.000 claims description 10
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
• 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 8
• 229940079593 drug Drugs 0.000 claims description 7
• 206010006895 Cachexia Diseases 0.000 claims description 6
• 230000001270 agonistic effect Effects 0.000 claims description 6
• 201000006549 dyspepsia Diseases 0.000 claims description 6
• 229940044601 receptor agonist Drugs 0.000 claims description 6
• 239000000018 receptor agonist Substances 0.000 claims description 6
• 125000001424 substituent group Chemical group 0.000 claims description 6
• SUJQKAFVJRKOOT-BVAGGSTKSA-N (3r)-n-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]piperidine-3-carboxamide Chemical compound C([C@@H](C(=O)N1CCC(CC1)N1C(=O)C(C2=CC=CC=C21)(C)C)NC(=O)[C@H]1CNCCC1)CC1=CC=CC=C1 SUJQKAFVJRKOOT-BVAGGSTKSA-N 0.000 claims description 5
• PIRYUGGCKGYCME-OZXSUGGESA-N (3s)-n-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]-3-(methylamino)pyrrolidine-1-carboxamide Chemical compound C1[C@@H](NC)CCN1C(=O)N[C@H](C(=O)N1CCC(CC1)N1C2=CC=CC=C2C(C)(C)C1=O)CCC1=CC=CC=C1 PIRYUGGCKGYCME-OZXSUGGESA-N 0.000 claims description 5
• 208000006083 Hypokinesia Diseases 0.000 claims description 5
• 206010021518 Impaired gastric emptying Diseases 0.000 claims description 5
• 201000005081 Intestinal Pseudo-Obstruction Diseases 0.000 claims description 5
• 206010028980 Neoplasm Diseases 0.000 claims description 5
• 239000005557 antagonist Substances 0.000 claims description 5
• 201000011510 cancer Diseases 0.000 claims description 5
• 239000003937 drug carrier Substances 0.000 claims description 5
• 208000001288 gastroparesis Diseases 0.000 claims description 5
• 230000003483 hypokinetic effect Effects 0.000 claims description 5
• 208000002551 irritable bowel syndrome Diseases 0.000 claims description 5
• JUAAZCIVIRFTDV-SQHAQQRYSA-N (3r)-n-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]-1-methylpiperidine-3-carboxamide Chemical compound C1N(C)CCC[C@H]1C(=O)N[C@H](C(=O)N1CCC(CC1)N1C2=CC=CC=C2C(C)(C)C1=O)CCC1=CC=CC=C1 JUAAZCIVIRFTDV-SQHAQQRYSA-N 0.000 claims description 4
• PMHBZGFTVBIEDK-GJZUVCINSA-N (3r)-n-[(2s)-1-[4-(5-fluoro-3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]piperidine-3-carboxamide Chemical compound C([C@@H](C(=O)N1CCC(CC1)N1C(=O)C(C2=CC(F)=CC=C21)(C)C)NC(=O)[C@H]1CNCCC1)CC1=CC=CC=C1 PMHBZGFTVBIEDK-GJZUVCINSA-N 0.000 claims description 4
• RSJXXLQTNHDVFQ-DHLKQENFSA-N 1-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]-3-[(3s)-pyrrolidin-3-yl]urea Chemical compound C([C@@H](C(=O)N1CCC(CC1)N1C(=O)C(C2=CC=CC=C21)(C)C)NC(=O)N[C@@H]1CNCC1)CC1=CC=CC=C1 RSJXXLQTNHDVFQ-DHLKQENFSA-N 0.000 claims description 4
• 206010010774 Constipation Diseases 0.000 claims description 4
• 208000011231 Crohn disease Diseases 0.000 claims description 4
• 206010052105 Gastrointestinal hypomotility Diseases 0.000 claims description 4
• 229940098749 Motilin receptor agonist Drugs 0.000 claims description 4
• 206010009887 colitis Diseases 0.000 claims description 4
• 206010012601 diabetes mellitus Diseases 0.000 claims description 4
• 238000004519 manufacturing process Methods 0.000 claims description 4
• QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims description 4
• 239000010802 sludge Substances 0.000 claims description 4
• 238000001356 surgical procedure Methods 0.000 claims description 4
• AOLDFDSXAJJDIO-BWKNWUBXSA-N (3r)-n-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-3-[2-(trifluoromethyl)phenyl]propan-2-yl]piperidine-3-carboxamide Chemical compound C([C@@H](C(=O)N1CCC(CC1)N1C(=O)C(C2=CC=CC=C21)(C)C)NC(=O)[C@H]1CNCCC1)C1=CC=CC=C1C(F)(F)F AOLDFDSXAJJDIO-BWKNWUBXSA-N 0.000 claims description 3
• OWMKHLDXAQDXGM-RDGATRHJSA-N (3r)-n-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-3-phenylpropan-2-yl]piperidine-3-carboxamide Chemical compound C([C@@H](C(=O)N1CCC(CC1)N1C(=O)C(C2=CC=CC=C21)(C)C)NC(=O)[C@H]1CNCCC1)C1=CC=CC=C1 OWMKHLDXAQDXGM-RDGATRHJSA-N 0.000 claims description 3
• XGEJCCLCXANNIR-BWKNWUBXSA-N (3r)-n-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-3-(2-fluorophenyl)-1-oxopropan-2-yl]piperidine-3-carboxamide Chemical compound C([C@@H](C(=O)N1CCC(CC1)N1C(=O)C(C2=CC=CC=C21)(C)C)NC(=O)[C@H]1CNCCC1)C1=CC=CC=C1F XGEJCCLCXANNIR-BWKNWUBXSA-N 0.000 claims description 3
• LMUHVYYXPZOKPF-BWKNWUBXSA-N (3r)-n-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-3-(3-fluorophenyl)-1-oxopropan-2-yl]piperidine-3-carboxamide Chemical compound C([C@@H](C(=O)N1CCC(CC1)N1C(=O)C(C2=CC=CC=C21)(C)C)NC(=O)[C@H]1CNCCC1)C1=CC=CC(F)=C1 LMUHVYYXPZOKPF-BWKNWUBXSA-N 0.000 claims description 3
• JMPQSGUNKHHXKE-BWKNWUBXSA-N (3r)-n-[(2s)-3-(2-chlorophenyl)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxopropan-2-yl]piperidine-3-carboxamide Chemical compound C([C@@H](C(=O)N1CCC(CC1)N1C(=O)C(C2=CC=CC=C21)(C)C)NC(=O)[C@H]1CNCCC1)C1=CC=CC=C1Cl JMPQSGUNKHHXKE-BWKNWUBXSA-N 0.000 claims description 3
• BIRKVPJXLVEMCG-DEOSSOPVSA-N 1-(2-amino-2-methylpropyl)-3-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]urea Chemical compound C([C@H](NC(=O)NCC(C)(N)C)C(=O)N1CCC(CC1)N1C2=CC=CC=C2C(C)(C)C1=O)CC1=CC=CC=C1 BIRKVPJXLVEMCG-DEOSSOPVSA-N 0.000 claims description 3
• SOXUZUZHRXAORE-MHZLTWQESA-N 1-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]-3-(4-ethylpiperidin-4-yl)urea Chemical compound N([C@@H](CCC=1C=CC=CC=1)C(=O)N1CCC(CC1)N1C2=CC=CC=C2C(C)(C)C1=O)C(=O)NC1(CC)CCNCC1 SOXUZUZHRXAORE-MHZLTWQESA-N 0.000 claims description 3
• YVWMKXMHOJIROP-SANMLTNESA-N 1-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]-3-(4-methylpiperidin-4-yl)urea Chemical compound C([C@@H](C(=O)N1CCC(CC1)N1C(=O)C(C2=CC=CC=C21)(C)C)NC(=O)NC1(C)CCNCC1)CC1=CC=CC=C1 YVWMKXMHOJIROP-SANMLTNESA-N 0.000 claims description 3
• VWZFFEYYECYQOP-BVAGGSTKSA-N 1-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]-3-[(3r)-piperidin-3-yl]urea Chemical compound C([C@@H](C(=O)N1CCC(CC1)N1C(=O)C(C2=CC=CC=C21)(C)C)NC(=O)N[C@H]1CNCCC1)CC1=CC=CC=C1 VWZFFEYYECYQOP-BVAGGSTKSA-N 0.000 claims description 3
• VKQQHTMBYGXNCC-BVAGGSTKSA-N 1-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]-3-[[(2r)-pyrrolidin-2-yl]methyl]urea Chemical compound C([C@@H](C(=O)N1CCC(CC1)N1C(=O)C(C2=CC=CC=C21)(C)C)NC(=O)NC[C@@H]1NCCC1)CC1=CC=CC=C1 VKQQHTMBYGXNCC-BVAGGSTKSA-N 0.000 claims description 3
• VKQQHTMBYGXNCC-OZXSUGGESA-N 1-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]-3-[[(2s)-pyrrolidin-2-yl]methyl]urea Chemical compound C([C@@H](C(=O)N1CCC(CC1)N1C(=O)C(C2=CC=CC=C21)(C)C)NC(=O)NC[C@H]1NCCC1)CC1=CC=CC=C1 VKQQHTMBYGXNCC-OZXSUGGESA-N 0.000 claims description 3
• GVZFYSOCPJTYMJ-BVAGGSTKSA-N 1-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]-3-[[(3r)-pyrrolidin-3-yl]methyl]urea Chemical compound C([C@@H](C(=O)N1CCC(CC1)N1C(=O)C(C2=CC=CC=C21)(C)C)NC(=O)NC[C@H]1CNCC1)CC1=CC=CC=C1 GVZFYSOCPJTYMJ-BVAGGSTKSA-N 0.000 claims description 3
• PRAUQPNEIHQQBD-VWLOTQADSA-N 1-[2-(dimethylamino)ethyl]-3-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]urea Chemical compound C([C@H](NC(=O)NCCN(C)C)C(=O)N1CCC(CC1)N1C2=CC=CC=C2C(C)(C)C1=O)CC1=CC=CC=C1 PRAUQPNEIHQQBD-VWLOTQADSA-N 0.000 claims description 3
• WTMHNAXPHQIRNZ-IGKIAQTJSA-N 3-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]-1-methyl-1-[[(2s)-pyrrolidin-2-yl]methyl]urea Chemical compound N([C@@H](CCC=1C=CC=CC=1)C(=O)N1CCC(CC1)N1C2=CC=CC=C2C(C)(C)C1=O)C(=O)N(C)C[C@@H]1CCCN1 WTMHNAXPHQIRNZ-IGKIAQTJSA-N 0.000 claims description 3
• 206010021639 Incontinence Diseases 0.000 claims description 3
• 241000124008 Mammalia Species 0.000 claims description 3
• 206010047700 Vomiting Diseases 0.000 claims description 3
• 239000013543 active substance Substances 0.000 claims description 3
• 230000000202 analgesic effect Effects 0.000 claims description 3
• 235000019789 appetite Nutrition 0.000 claims description 3
• 230000036528 appetite Effects 0.000 claims description 3
• 208000003243 intestinal obstruction Diseases 0.000 claims description 3
• HXKCOXFOJCNVJP-VWLOTQADSA-N n-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-3-[2-(trifluoromethyl)phenyl]propan-2-yl]piperidine-4-carboxamide Chemical compound C([C@@H](C(=O)N1CCC(CC1)N1C(=O)C(C2=CC=CC=C21)(C)C)NC(=O)C1CCNCC1)C1=CC=CC=C1C(F)(F)F HXKCOXFOJCNVJP-VWLOTQADSA-N 0.000 claims description 3
• GIOBFJUYHPVVOX-VWLOTQADSA-N n-[(2s)-3-(4-chlorophenyl)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxopropan-2-yl]piperidine-4-carboxamide Chemical compound C([C@@H](C(=O)N1CCC(CC1)N1C(=O)C(C2=CC=CC=C21)(C)C)NC(=O)C1CCNCC1)C1=CC=C(Cl)C=C1 GIOBFJUYHPVVOX-VWLOTQADSA-N 0.000 claims description 3
• 230000036407 pain Effects 0.000 claims description 3
• 230000001769 paralizing effect Effects 0.000 claims description 3
• LCDCPQHFCOBUEF-UHFFFAOYSA-N pyrrolidine-1-carboxamide Chemical compound NC(=O)N1CCCC1 LCDCPQHFCOBUEF-UHFFFAOYSA-N 0.000 claims description 3
• 230000008673 vomiting Effects 0.000 claims description 3
• JFVSUBWINXXICZ-AZGAKELHSA-N (2s)-2-amino-n-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]-3,3-dimethylbutanamide Chemical compound C([C@H](NC(=O)[C@@H](N)C(C)(C)C)C(=O)N1CCC(CC1)N1C2=CC=CC=C2C(C)(C)C1=O)CC1=CC=CC=C1 JFVSUBWINXXICZ-AZGAKELHSA-N 0.000 claims description 2
• NUMDEMPVMRLUAJ-UIOOFZCWSA-N (2s)-n-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]piperidine-2-carboxamide Chemical compound C([C@@H](C(=O)N1CCC(CC1)N1C(=O)C(C2=CC=CC=C21)(C)C)NC(=O)[C@H]1NCCCC1)CC1=CC=CC=C1 NUMDEMPVMRLUAJ-UIOOFZCWSA-N 0.000 claims description 2
• ASTZPWGSMZUPMR-GJZUVCINSA-N (3r)-n-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]-3-methylpiperazine-1-carboxamide Chemical compound C1CN[C@H](C)CN1C(=O)N[C@H](C(=O)N1CCC(CC1)N1C2=CC=CC=C2C(C)(C)C1=O)CCC1=CC=CC=C1 ASTZPWGSMZUPMR-GJZUVCINSA-N 0.000 claims description 2
• AAGPPBBGUDJEPY-BWKNWUBXSA-N (3r)-n-[(2s)-3-(4-chlorophenyl)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxopropan-2-yl]piperidine-3-carboxamide Chemical compound C([C@@H](C(=O)N1CCC(CC1)N1C(=O)C(C2=CC=CC=C21)(C)C)NC(=O)[C@H]1CNCCC1)C1=CC=C(Cl)C=C1 AAGPPBBGUDJEPY-BWKNWUBXSA-N 0.000 claims description 2
• DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims description 2
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
• HAEAQWKYVREOIL-MHZLTWQESA-N 1-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]-3-(1,4-dimethylpiperidin-4-yl)urea Chemical compound C1CN(C)CCC1(C)NC(=O)N[C@H](C(=O)N1CCC(CC1)N1C2=CC=CC=C2C(C)(C)C1=O)CCC1=CC=CC=C1 HAEAQWKYVREOIL-MHZLTWQESA-N 0.000 claims description 2
• QXHHOTWZDARDPY-MHZLTWQESA-N 1-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]-3-(2-pyrrolidin-1-ylethyl)urea Chemical compound C([C@@H](C(=O)N1CCC(CC1)N1C(=O)C(C2=CC=CC=C21)(C)C)NC(=O)NCCN1CCCC1)CC1=CC=CC=C1 QXHHOTWZDARDPY-MHZLTWQESA-N 0.000 claims description 2
• RSJXXLQTNHDVFQ-RDGATRHJSA-N 1-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]-3-[(3r)-pyrrolidin-3-yl]urea Chemical compound C([C@@H](C(=O)N1CCC(CC1)N1C(=O)C(C2=CC=CC=C21)(C)C)NC(=O)N[C@H]1CNCC1)CC1=CC=CC=C1 RSJXXLQTNHDVFQ-RDGATRHJSA-N 0.000 claims description 2
• FOTUFEMSHXWDCH-BDYUSTAISA-N 1-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]-3-[[(2s)-1-methylpyrrolidin-2-yl]methyl]urea Chemical compound CN1CCC[C@H]1CNC(=O)N[C@H](C(=O)N1CCC(CC1)N1C2=CC=CC=C2C(C)(C)C1=O)CCC1=CC=CC=C1 FOTUFEMSHXWDCH-BDYUSTAISA-N 0.000 claims description 2
• ZLXHOBNMQAMSHB-SQHAQQRYSA-N 1-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]-3-[[(3r)-piperidin-3-yl]methyl]urea Chemical compound C([C@@H](C(=O)N1CCC(CC1)N1C(=O)C(C2=CC=CC=C21)(C)C)NC(=O)NC[C@H]1CNCCC1)CC1=CC=CC=C1 ZLXHOBNMQAMSHB-SQHAQQRYSA-N 0.000 claims description 2
• LKEZAXJRBUUBQQ-SANMLTNESA-N 1-[(2s)-1-[4-(5-fluoro-3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]-3-(4-methylpiperidin-4-yl)urea Chemical compound C([C@@H](C(=O)N1CCC(CC1)N1C(=O)C(C2=CC(F)=CC=C21)(C)C)NC(=O)NC1(C)CCNCC1)CC1=CC=CC=C1 LKEZAXJRBUUBQQ-SANMLTNESA-N 0.000 claims description 2
• OCXOKEUQIIJEKP-OZXSUGGESA-N 1-[(2s)-1-[4-(5-fluoro-3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]-3-[[(2s)-pyrrolidin-2-yl]methyl]urea Chemical compound C([C@@H](C(=O)N1CCC(CC1)N1C(=O)C(C2=CC(F)=CC=C21)(C)C)NC(=O)NC[C@H]1NCCC1)CC1=CC=CC=C1 OCXOKEUQIIJEKP-OZXSUGGESA-N 0.000 claims description 2
• 102100038019 Corticotropin-releasing factor receptor 2 Human genes 0.000 claims description 2
• 101000878664 Homo sapiens Corticotropin-releasing factor receptor 2 Proteins 0.000 claims description 2
• 102000009493 Neurokinin receptors Human genes 0.000 claims description 2
• 108050000302 Neurokinin receptors Proteins 0.000 claims description 2
• 108010016076 Octreotide Proteins 0.000 claims description 2
• 101150084577 SST2 gene Proteins 0.000 claims description 2
• 102000003566 TRPV1 Human genes 0.000 claims description 2
• 101150016206 Trpv1 gene Proteins 0.000 claims description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 2
• 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 2
• 239000004202 carbamide Substances 0.000 claims description 2
• 125000006312 cyclopentyl amino group Chemical group [H]N(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
• AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 claims description 2
• 210000004211 gastric acid Anatomy 0.000 claims description 2
• 229940077716 histamine h2 receptor antagonists for peptic ulcer and gord Drugs 0.000 claims description 2
• IDNCVQCWTIJXBD-DEOSSOPVSA-N n-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]azetidine-3-carboxamide Chemical compound C([C@@H](C(=O)N1CCC(CC1)N1C(=O)C(C2=CC=CC=C21)(C)C)NC(=O)C1CNC1)CC1=CC=CC=C1 IDNCVQCWTIJXBD-DEOSSOPVSA-N 0.000 claims description 2
• PQAWEOXYRRAYNI-SANMLTNESA-N n-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]piperidine-4-carboxamide Chemical compound C([C@@H](C(=O)N1CCC(CC1)N1C(=O)C(C2=CC=CC=C21)(C)C)NC(=O)C1CCNCC1)CC1=CC=CC=C1 PQAWEOXYRRAYNI-SANMLTNESA-N 0.000 claims description 2
• LMJVHFIHVNHVDL-VWLOTQADSA-N n-[(2s)-3-(2-chlorophenyl)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxopropan-2-yl]piperidine-4-carboxamide Chemical compound C([C@@H](C(=O)N1CCC(CC1)N1C(=O)C(C2=CC=CC=C21)(C)C)NC(=O)C1CCNCC1)C1=CC=CC=C1Cl LMJVHFIHVNHVDL-VWLOTQADSA-N 0.000 claims description 2
• 229960002700 octreotide Drugs 0.000 claims description 2
• 239000000612 proton pump inhibitor Substances 0.000 claims description 2
• 229940126409 proton pump inhibitor Drugs 0.000 claims description 2
• 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 claims description 2
• 230000004060 metabolic process Effects 0.000 claims 2
• 239000003185 4 aminobutyric acid B receptor stimulating agent Substances 0.000 claims 1
• 208000037821 progressive disease Diseases 0.000 claims 1
• 239000003378 sodium channel stimulating agent Substances 0.000 claims 1
• 239000000126 substance Substances 0.000 abstract description 62
• 102100033818 Motilin receptor Human genes 0.000 abstract description 21
• 101001132878 Homo sapiens Motilin receptor Proteins 0.000 abstract description 2
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 135
• 239000000203 mixture Substances 0.000 description 89
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 87
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 69
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 66
• 239000000243 solution Substances 0.000 description 46
• 238000004128 high performance liquid chromatography Methods 0.000 description 42
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
• 238000006243 chemical reaction Methods 0.000 description 29
• 230000014759 maintenance of location Effects 0.000 description 28
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 27
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 25
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 25
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 24
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 22
• 239000000543 intermediate Substances 0.000 description 22
• 238000012799 strong cation exchange Methods 0.000 description 20
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
• LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 18
• 101800002372 Motilin Proteins 0.000 description 18
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
• 125000006239 protecting group Chemical group 0.000 description 18
• 235000001014 amino acid Nutrition 0.000 description 17
• 239000003153 chemical reaction reagent Substances 0.000 description 17
• 238000002360 preparation method Methods 0.000 description 17
• 239000002904 solvent Substances 0.000 description 17
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
• 102000002419 Motilin Human genes 0.000 description 16
• 150000001413 amino acids Chemical class 0.000 description 16
• 239000002585 base Substances 0.000 description 16
• 239000012044 organic layer Substances 0.000 description 15
• ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 14
• 238000005481 NMR spectroscopy Methods 0.000 description 14
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 14
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
• 150000001412 amines Chemical class 0.000 description 12
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
• 229910021529 ammonia Inorganic materials 0.000 description 11
• 230000002496 gastric effect Effects 0.000 description 11
• 239000012442 inert solvent Substances 0.000 description 11
• 239000002243 precursor Substances 0.000 description 11
• 239000011541 reaction mixture Substances 0.000 description 11
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
• 235000017557 sodium bicarbonate Nutrition 0.000 description 11
• 229910052938 sodium sulfate Inorganic materials 0.000 description 11
• 235000011152 sodium sulphate Nutrition 0.000 description 11
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
• 235000019441 ethanol Nutrition 0.000 description 10
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
• 239000003643 water by type Substances 0.000 description 10
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
• 0 CC(C(*)(*)c1c(C)cccc1)=O Chemical compound CC(C(*)(*)c1c(C)cccc1)=O 0.000 description 9
• SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 9
• 239000007864 aqueous solution Substances 0.000 description 9
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 9
• 230000002829 reductive effect Effects 0.000 description 9
• 239000003981 vehicle Substances 0.000 description 9
• VCAXPZZEPPJDRM-BOXHHOBZSA-N 1-[1-[(2s)-2-amino-4-phenylbutanoyl]piperidin-4-yl]-3,3-dimethylindol-2-one;hydrochloride Chemical compound Cl.C([C@H](N)C(=O)N1CCC(CC1)N1C(=O)C(C2=CC=CC=C21)(C)C)CC1=CC=CC=C1 VCAXPZZEPPJDRM-BOXHHOBZSA-N 0.000 description 8
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
• 239000012267 brine Substances 0.000 description 8
• 239000000460 chlorine Substances 0.000 description 8
• 239000011159 matrix material Substances 0.000 description 8
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
• 102000005962 receptors Human genes 0.000 description 8
• 108020003175 receptors Proteins 0.000 description 8
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
• 239000007787 solid Substances 0.000 description 8
• 239000007790 solid phase Substances 0.000 description 8
• 238000004809 thin layer chromatography Methods 0.000 description 8
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
• NXILIHONWRXHFA-MRVPVSSYSA-N (3r)-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-3-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H](C(O)=O)C1 NXILIHONWRXHFA-MRVPVSSYSA-N 0.000 description 7
• WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 7
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
• 239000000706 filtrate Substances 0.000 description 7
• 238000001727 in vivo Methods 0.000 description 7
• 230000003287 optical effect Effects 0.000 description 7
• 108090000765 processed proteins & peptides Proteins 0.000 description 7
• 238000010898 silica gel chromatography Methods 0.000 description 7
• 238000003756 stirring Methods 0.000 description 7
• 239000000725 suspension Substances 0.000 description 7
• 238000003786 synthesis reaction Methods 0.000 description 7
• XYKYUXYNQDXZTD-QMMMGPOBSA-N tert-butyl n-methyl-n-[(3s)-pyrrolidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N(C)[C@H]1CCNC1 XYKYUXYNQDXZTD-QMMMGPOBSA-N 0.000 description 7
• BETBOAZCLSJOBQ-NSHDSACASA-N (2s)-3-(4-chlorophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=C(Cl)C=C1 BETBOAZCLSJOBQ-NSHDSACASA-N 0.000 description 6
• 238000005160 1H NMR spectroscopy Methods 0.000 description 6
• GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 6
• WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
• JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 6
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
• JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 6
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
• FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 6
• 238000005859 coupling reaction Methods 0.000 description 6
• GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 description 6
• 229960003276 erythromycin Drugs 0.000 description 6
• 210000001035 gastrointestinal tract Anatomy 0.000 description 6
• 229910052740 iodine Inorganic materials 0.000 description 6
• 229910052763 palladium Inorganic materials 0.000 description 6
• 230000008855 peristalsis Effects 0.000 description 6
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
• 229920006395 saturated elastomer Polymers 0.000 description 6
• 235000011121 sodium hydroxide Nutrition 0.000 description 6
• RDHXHFVOCIMACS-DTWKUNHWSA-N (1s,3r)-3-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]cyclopentane-1-carboxylic acid Chemical compound CC(C)(C)OC(=O)N(C)[C@@H]1CC[C@H](C(O)=O)C1 RDHXHFVOCIMACS-DTWKUNHWSA-N 0.000 description 5
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 5
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
• DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 5
• 150000001408 amides Chemical class 0.000 description 5
• LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical compound O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 description 5
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
• 239000003054 catalyst Substances 0.000 description 5
• 229910052801 chlorine Inorganic materials 0.000 description 5
• 239000000499 gel Substances 0.000 description 5
• 125000000623 heterocyclic group Chemical group 0.000 description 5
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
• 235000019341 magnesium sulphate Nutrition 0.000 description 5
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
• LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 5
• 239000003921 oil Substances 0.000 description 5
• 235000019198 oils Nutrition 0.000 description 5
• 239000000651 prodrug Substances 0.000 description 5
• 229940002612 prodrug Drugs 0.000 description 5
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
• 239000003039 volatile agent Substances 0.000 description 5
• NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 4
• SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 4
• PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 4
• OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 4
• HYOOXXQFBONQDD-UHFFFAOYSA-N 3,3-dimethyl-1-piperidin-4-ylindol-2-one;hydrochloride Chemical compound Cl.C12=CC=CC=C2C(C)(C)C(=O)N1C1CCNCC1 HYOOXXQFBONQDD-UHFFFAOYSA-N 0.000 description 4
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
• ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 4
• FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 4
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
• 230000029936 alkylation Effects 0.000 description 4
• 238000005804 alkylation reaction Methods 0.000 description 4
• 238000004458 analytical method Methods 0.000 description 4
• 230000008901 benefit Effects 0.000 description 4
• 229910052794 bromium Inorganic materials 0.000 description 4
• 150000001721 carbon Chemical group 0.000 description 4
• MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 4
• 238000004440 column chromatography Methods 0.000 description 4
• 230000008878 coupling Effects 0.000 description 4
• 238000010168 coupling process Methods 0.000 description 4
• 239000012043 crude product Substances 0.000 description 4
• 150000002148 esters Chemical class 0.000 description 4
• 235000019253 formic acid Nutrition 0.000 description 4
• 230000006870 function Effects 0.000 description 4
• 230000005714 functional activity Effects 0.000 description 4
• NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
• 239000011630 iodine Substances 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 239000002245 particle Substances 0.000 description 4
• 238000005897 peptide coupling reaction Methods 0.000 description 4
• 235000011118 potassium hydroxide Nutrition 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• 239000003755 preservative agent Substances 0.000 description 4
• 239000003586 protic polar solvent Substances 0.000 description 4
• 238000000746 purification Methods 0.000 description 4
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
• 239000012321 sodium triacetoxyborohydride Substances 0.000 description 4
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
• 239000000375 suspending agent Substances 0.000 description 4
• VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
• TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 4
• ZYJPUMXJBDHSIF-NSHDSACASA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZYJPUMXJBDHSIF-NSHDSACASA-N 0.000 description 3
• LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
• FZUFYNBNRFNPCZ-NRFANRHFSA-N 1-[1-[(2s)-2-amino-4-phenylbutanoyl]piperidin-4-yl]-3,3-dimethylindol-2-one Chemical compound C([C@H](N)C(=O)N1CCC(CC1)N1C(=O)C(C2=CC=CC=C21)(C)C)CC1=CC=CC=C1 FZUFYNBNRFNPCZ-NRFANRHFSA-N 0.000 description 3
• UBJYNTVRIMOXKW-NRFANRHFSA-N 1-[1-[(2s)-2-amino-4-phenylbutanoyl]piperidin-4-yl]-5-fluoro-3,3-dimethylindol-2-one Chemical compound C([C@H](N)C(=O)N1CCC(CC1)N1C(=O)C(C2=CC(F)=CC=C21)(C)C)CC1=CC=CC=C1 UBJYNTVRIMOXKW-NRFANRHFSA-N 0.000 description 3
• JHFAEUICJHBVHB-UHFFFAOYSA-N 1h-indol-2-ol Chemical class C1=CC=C2NC(O)=CC2=C1 JHFAEUICJHBVHB-UHFFFAOYSA-N 0.000 description 3
• RGUKYNXWOWSRET-UHFFFAOYSA-N 4-pyrrolidin-1-ylpyridine Chemical compound C1CCCN1C1=CC=NC=C1 RGUKYNXWOWSRET-UHFFFAOYSA-N 0.000 description 3
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
• 150000008574 D-amino acids Chemical class 0.000 description 3
• QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
• XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
• QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 150000008575 L-amino acids Chemical group 0.000 description 3
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
• OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 3
• 150000007513 acids Chemical class 0.000 description 3
• 229910052783 alkali metal Inorganic materials 0.000 description 3
• 150000003862 amino acid derivatives Chemical class 0.000 description 3
• 239000000823 artificial membrane Substances 0.000 description 3
• 230000015572 biosynthetic process Effects 0.000 description 3
• 210000004556 brain Anatomy 0.000 description 3
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
• 229910002091 carbon monoxide Inorganic materials 0.000 description 3
• FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 3
• 239000002270 dispersing agent Substances 0.000 description 3
• 238000009826 distribution Methods 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 239000000839 emulsion Substances 0.000 description 3
• FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 3
• 238000002474 experimental method Methods 0.000 description 3
• 229910052731 fluorine Inorganic materials 0.000 description 3
• 239000011737 fluorine Substances 0.000 description 3
• 238000002825 functional assay Methods 0.000 description 3
• 239000001963 growth medium Substances 0.000 description 3
• 125000005843 halogen group Chemical group 0.000 description 3
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
• 238000011534 incubation Methods 0.000 description 3
• 210000000936 intestine Anatomy 0.000 description 3
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
• 230000003278 mimic effect Effects 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• 239000002674 ointment Substances 0.000 description 3
• 239000000546 pharmaceutical excipient Substances 0.000 description 3
• 150000003053 piperidines Chemical class 0.000 description 3
• 229910000027 potassium carbonate Inorganic materials 0.000 description 3
• 235000011181 potassium carbonates Nutrition 0.000 description 3
• 239000000047 product Substances 0.000 description 3
• 239000000377 silicon dioxide Substances 0.000 description 3
• 239000012312 sodium hydride Substances 0.000 description 3
• 229910000104 sodium hydride Inorganic materials 0.000 description 3
• 239000012453 solvate Substances 0.000 description 3
• 239000003381 stabilizer Substances 0.000 description 3
• 210000002784 stomach Anatomy 0.000 description 3
• 229940124530 sulfonamide Drugs 0.000 description 3
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 3
• YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 3
• 210000001186 vagus nerve Anatomy 0.000 description 3
• MCODLPJUFHPVQP-GFCCVEGCSA-N (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-phenylbutanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](C(O)=O)CCC1=CC=CC=C1 MCODLPJUFHPVQP-GFCCVEGCSA-N 0.000 description 2
• MCODLPJUFHPVQP-LBPRGKRZSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-phenylbutanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CCC1=CC=CC=C1 MCODLPJUFHPVQP-LBPRGKRZSA-N 0.000 description 2
• HVJSITPJGZYZLH-YWEHKCAJSA-N (3r)-n-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]-n-methylpiperidine-3-carboxamide Chemical compound C([C@H](N(C)C(=O)[C@H]1CNCCC1)C(=O)N1CCC(CC1)N1C2=CC=CC=C2C(C)(C)C1=O)CC1=CC=CC=C1 HVJSITPJGZYZLH-YWEHKCAJSA-N 0.000 description 2
• 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
• OCJBOOLMMGQPQU-UHFFFAOYSA-N 1,4-dichlorobenzene Chemical compound ClC1=CC=C(Cl)C=C1 OCJBOOLMMGQPQU-UHFFFAOYSA-N 0.000 description 2
• ZNXJYKUZUOEJAV-UHFFFAOYSA-N 1-(1-benzylpiperidin-4-yl)-3,3-dimethylindol-2-one Chemical compound C12=CC=CC=C2C(C)(C)C(=O)N1C(CC1)CCN1CC1=CC=CC=C1 ZNXJYKUZUOEJAV-UHFFFAOYSA-N 0.000 description 2
• MZFMPDDEWRYRFT-UHFFFAOYSA-N 1-(1-benzylpiperidin-4-yl)-5-fluoro-3,3-dimethylindol-2-one Chemical compound C12=CC=C(F)C=C2C(C)(C)C(=O)N1C(CC1)CCN1CC1=CC=CC=C1 MZFMPDDEWRYRFT-UHFFFAOYSA-N 0.000 description 2
• MSKHCMRUDDYZGG-YWEHKCAJSA-N 1-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]-1-methyl-3-[(3r)-piperidin-3-yl]urea Chemical compound C([C@H](N(C)C(=O)N[C@H]1CNCCC1)C(=O)N1CCC(CC1)N1C2=CC=CC=C2C(C)(C)C1=O)CC1=CC=CC=C1 MSKHCMRUDDYZGG-YWEHKCAJSA-N 0.000 description 2
• CWXVXWQQZOZPQQ-IGKIAQTJSA-N 1-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]-3-[[(2s)-piperidin-2-yl]methyl]urea Chemical compound C([C@@H](C(=O)N1CCC(CC1)N1C(=O)C(C2=CC=CC=C21)(C)C)NC(=O)NC[C@H]1NCCCC1)CC1=CC=CC=C1 CWXVXWQQZOZPQQ-IGKIAQTJSA-N 0.000 description 2
• FZUFYNBNRFNPCZ-OAQYLSRUSA-N 1-[1-[(2r)-2-amino-4-phenylbutanoyl]piperidin-4-yl]-3,3-dimethylindol-2-one Chemical compound C([C@@H](N)C(=O)N1CCC(CC1)N1C(=O)C(C2=CC=CC=C21)(C)C)CC1=CC=CC=C1 FZUFYNBNRFNPCZ-OAQYLSRUSA-N 0.000 description 2
• TTZNXTDIPQVIFO-FQEVSTJZSA-N 1-[1-[(2s)-2-amino-3-(4-chlorophenyl)propanoyl]piperidin-4-yl]-3,3-dimethylindol-2-one Chemical compound C([C@H](N)C(=O)N1CCC(CC1)N1C(=O)C(C2=CC=CC=C21)(C)C)C1=CC=C(Cl)C=C1 TTZNXTDIPQVIFO-FQEVSTJZSA-N 0.000 description 2
• PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 2
• NVYAJHUUOSUSGC-UHFFFAOYSA-N 2-(2-bromo-5-fluorophenyl)-2-methylpropanoic acid Chemical compound OC(=O)C(C)(C)C1=CC(F)=CC=C1Br NVYAJHUUOSUSGC-UHFFFAOYSA-N 0.000 description 2
• SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 2
• OZMLUMPWPFZWTP-UHFFFAOYSA-N 2-(tributyl-$l^{5}-phosphanylidene)acetonitrile Chemical compound CCCCP(CCCC)(CCCC)=CC#N OZMLUMPWPFZWTP-UHFFFAOYSA-N 0.000 description 2
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
• XIYHVTYIQQXXMI-QFIPXVFZSA-N 2-chloro-n-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]acetamide Chemical compound C([C@@H](C(=O)N1CCC(CC1)N1C(=O)C(C2=CC=CC=C21)(C)C)NC(=O)CCl)CC1=CC=CC=C1 XIYHVTYIQQXXMI-QFIPXVFZSA-N 0.000 description 2
• YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 2
• RFBSYDCQZYNAPH-QFIPXVFZSA-N 3,3-dimethyl-1-[1-[(2s)-2-(methylamino)-4-phenylbutanoyl]piperidin-4-yl]indol-2-one Chemical compound C([C@H](NC)C(=O)N1CCC(CC1)N1C2=CC=CC=C2C(C)(C)C1=O)CC1=CC=CC=C1 RFBSYDCQZYNAPH-QFIPXVFZSA-N 0.000 description 2
• OGYLDTLJKYCYTB-UHFFFAOYSA-N 5-fluoro-3,3-dimethyl-1-piperidin-4-ylindol-2-one Chemical compound C12=CC=C(F)C=C2C(C)(C)C(=O)N1C1CCNCC1 OGYLDTLJKYCYTB-UHFFFAOYSA-N 0.000 description 2
• USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
• 239000005695 Ammonium acetate Substances 0.000 description 2
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
• 206010002091 Anaesthesia Diseases 0.000 description 2
• QWUVFVIGMLDHII-JTQLQIEISA-N CC([C@H](Cc1ccccc1F)N)=O Chemical compound CC([C@H](Cc1ccccc1F)N)=O QWUVFVIGMLDHII-JTQLQIEISA-N 0.000 description 2
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
• 238000005727 Friedel-Crafts reaction Methods 0.000 description 2
• 108010051696 Growth Hormone Proteins 0.000 description 2
• 239000007995 HEPES buffer Substances 0.000 description 2
• 239000012981 Hank's balanced salt solution Substances 0.000 description 2
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• 238000006751 Mitsunobu reaction Methods 0.000 description 2
• LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
• MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
• PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
• CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
• 229930040373 Paraformaldehyde Natural products 0.000 description 2
• 229930182555 Penicillin Natural products 0.000 description 2
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
• 102100038803 Somatotropin Human genes 0.000 description 2
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
• XOTKTEZINREEJF-UHFFFAOYSA-N [1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamic acid Chemical compound C12=CC=CC=C2C(C)(C)C(=O)N1C(CC1)CCN1C(=O)C(NC(O)=O)CCC1=CC=CC=C1 XOTKTEZINREEJF-UHFFFAOYSA-N 0.000 description 2
• QYIZFILWBZFKCY-UHFFFAOYSA-N [1-[4-(5-fluoro-3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamic acid Chemical compound C12=CC=C(F)C=C2C(C)(C)C(=O)N1C(CC1)CCN1C(=O)C(NC(O)=O)CCC1=CC=CC=C1 QYIZFILWBZFKCY-UHFFFAOYSA-N 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 210000000577 adipose tissue Anatomy 0.000 description 2
• 230000002411 adverse Effects 0.000 description 2
• 125000003545 alkoxy group Chemical group 0.000 description 2
• 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
• 125000000539 amino acid group Chemical group 0.000 description 2
• 125000003277 amino group Chemical group 0.000 description 2
• 235000019257 ammonium acetate Nutrition 0.000 description 2
• 229940043376 ammonium acetate Drugs 0.000 description 2
• 235000011114 ammonium hydroxide Nutrition 0.000 description 2
• 238000001949 anaesthesia Methods 0.000 description 2
• 230000037005 anaesthesia Effects 0.000 description 2
• 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
• 238000011914 asymmetric synthesis Methods 0.000 description 2
• 239000012298 atmosphere Substances 0.000 description 2
• RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 2
• 229910001863 barium hydroxide Inorganic materials 0.000 description 2
• 230000003115 biocidal effect Effects 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
• 239000003638 chemical reducing agent Substances 0.000 description 2
• IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
• 239000012230 colorless oil Substances 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• 229940117389 dichlorobenzene Drugs 0.000 description 2
• DMGLSPAZGKUICV-UHFFFAOYSA-N dimethyl 2-(tributyl-$l^{5}-phosphanylidene)propanedioate Chemical compound CCCCP(CCCC)(CCCC)=C(C(=O)OC)C(=O)OC DMGLSPAZGKUICV-UHFFFAOYSA-N 0.000 description 2
• NCBFTYFOPLPRBX-UHFFFAOYSA-N dimethyl azodicarboxylate Substances COC(=O)N=NC(=O)OC NCBFTYFOPLPRBX-UHFFFAOYSA-N 0.000 description 2
• HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 2
• SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
• 230000020595 eating behavior Effects 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 150000002170 ethers Chemical class 0.000 description 2
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
• 238000011049 filling Methods 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• 230000030136 gastric emptying Effects 0.000 description 2
• 239000000122 growth hormone Substances 0.000 description 2
• 150000008282 halocarbons Chemical class 0.000 description 2
• GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
• 150000004677 hydrates Chemical class 0.000 description 2
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
• IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
• 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
• 230000002209 hydrophobic effect Effects 0.000 description 2
• 238000011065 in-situ storage Methods 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• 125000005647 linker group Chemical group 0.000 description 2
• 229910052744 lithium Inorganic materials 0.000 description 2
• ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
• 239000006210 lotion Substances 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 238000004949 mass spectrometry Methods 0.000 description 2
• 230000002503 metabolic effect Effects 0.000 description 2
• 239000002184 metal Chemical group 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• NCBFTYFOPLPRBX-AATRIKPKSA-N methyl (ne)-n-methoxycarbonyliminocarbamate Chemical compound COC(=O)\N=N\C(=O)OC NCBFTYFOPLPRBX-AATRIKPKSA-N 0.000 description 2
• 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
• BLPWJKHDQGIDKZ-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)-2-(2-bromo-5-fluorophenyl)-2-methylpropanamide Chemical compound C=1C(F)=CC=C(Br)C=1C(C)(C)C(=O)NC(CC1)CCN1CC1=CC=CC=C1 BLPWJKHDQGIDKZ-UHFFFAOYSA-N 0.000 description 2
• YVMIOSNKJVYQRJ-VWLOTQADSA-N n-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]-2-nitrobenzenesulfonamide Chemical compound C([C@@H](C(=O)N1CCC(CC1)N1C(=O)C(C2=CC=CC=C21)(C)C)NS(=O)(=O)C=1C(=CC=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 YVMIOSNKJVYQRJ-VWLOTQADSA-N 0.000 description 2
• PBMLIGRDJYOEIA-NDEPHWFRSA-N n-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]-n-methyl-2-nitrobenzenesulfonamide Chemical compound C([C@H](N(C)S(=O)(=O)C=1C(=CC=CC=1)[N+]([O-])=O)C(=O)N1CCC(CC1)N1C2=CC=CC=C2C(C)(C)C1=O)CC1=CC=CC=C1 PBMLIGRDJYOEIA-NDEPHWFRSA-N 0.000 description 2
• BVOCPVIXARZNQN-UHFFFAOYSA-N nipecotamide Chemical compound NC(=O)C1CCCNC1 BVOCPVIXARZNQN-UHFFFAOYSA-N 0.000 description 2
• 150000002825 nitriles Chemical class 0.000 description 2
• 238000010534 nucleophilic substitution reaction Methods 0.000 description 2
• 235000016709 nutrition Nutrition 0.000 description 2
• 230000035764 nutrition Effects 0.000 description 2
• 229920002866 paraformaldehyde Polymers 0.000 description 2
• 229940049954 penicillin Drugs 0.000 description 2
• FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
• 230000035699 permeability Effects 0.000 description 2
• 239000012071 phase Substances 0.000 description 2
• HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
• 238000002600 positron emission tomography Methods 0.000 description 2
• 239000011736 potassium bicarbonate Substances 0.000 description 2
• 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
• 235000015497 potassium bicarbonate Nutrition 0.000 description 2
• TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
• 229940086066 potassium hydrogencarbonate Drugs 0.000 description 2
• 238000002953 preparative HPLC Methods 0.000 description 2
• 230000002335 preservative effect Effects 0.000 description 2
• 230000001737 promoting effect Effects 0.000 description 2
• VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 2
• WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 238000002603 single-photon emission computed tomography Methods 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 229910000029 sodium carbonate Inorganic materials 0.000 description 2
• 235000017550 sodium carbonate Nutrition 0.000 description 2
• DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
• 230000000707 stereoselective effect Effects 0.000 description 2
• 229960005322 streptomycin Drugs 0.000 description 2
• 238000006467 substitution reaction Methods 0.000 description 2
• HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 2
• 150000003456 sulfonamides Chemical class 0.000 description 2
• 150000003462 sulfoxides Chemical class 0.000 description 2
• 239000000829 suppository Substances 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• UYJKDWNBKZBGTA-DEOSSOPVSA-N tert-butyl n-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C([C@H](NC(=O)OC(C)(C)C)C(=O)N1CCC(CC1)N1C2=CC=CC=C2C(C)(C)C1=O)CC1=CC=CC=C1 UYJKDWNBKZBGTA-DEOSSOPVSA-N 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 239000002562 thickening agent Substances 0.000 description 2
• CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 2
• 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 2
• FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 2
• 239000000080 wetting agent Substances 0.000 description 2
• 239000008096 xylene Substances 0.000 description 2
• RNJQBGXOSAQQDG-JGVFFNPUSA-N (1s,3r)-3-[(2-methylpropan-2-yl)oxycarbonylamino]cyclopentane-1-carboxylic acid Chemical compound CC(C)(C)OC(=O)N[C@@H]1CC[C@H](C(O)=O)C1 RNJQBGXOSAQQDG-JGVFFNPUSA-N 0.000 description 1
• HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
• OBETXYAYXDNJHR-SSDOTTSWSA-M (2r)-2-ethylhexanoate Chemical compound CCCC[C@@H](CC)C([O-])=O OBETXYAYXDNJHR-SSDOTTSWSA-M 0.000 description 1
• JQAOHGMPAAWWQO-QMMMGPOBSA-N (2s)-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCCC[C@H]1C(O)=O JQAOHGMPAAWWQO-QMMMGPOBSA-N 0.000 description 1
• FMCAFXHLMUOIGG-JTJHWIPRSA-N (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-JTJHWIPRSA-N 0.000 description 1
• VLSDXINSOMDCBK-BQYQJAHWSA-N (E)-1,1'-azobis(N,N-dimethylformamide) Chemical compound CN(C)C(=O)\N=N\C(=O)N(C)C VLSDXINSOMDCBK-BQYQJAHWSA-N 0.000 description 1
• SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 description 1
• ZRIOIQJUIUJPED-UHFFFAOYSA-N 1-(1-benzylpiperidin-4-yl)-3h-indol-2-one Chemical compound O=C1CC2=CC=CC=C2N1C(CC1)CCN1CC1=CC=CC=C1 ZRIOIQJUIUJPED-UHFFFAOYSA-N 0.000 description 1
• CKRWTEFJVOEAGB-DEOSSOPVSA-N 1-(azetidin-3-yl)-3-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]urea Chemical compound C([C@@H](C(=O)N1CCC(CC1)N1C(=O)C(C2=CC=CC=C21)(C)C)NC(=O)NC1CNC1)CC1=CC=CC=C1 CKRWTEFJVOEAGB-DEOSSOPVSA-N 0.000 description 1
• ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
• JWOHBPPVVDQMKB-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC(C(O)=O)CC1 JWOHBPPVVDQMKB-UHFFFAOYSA-N 0.000 description 1
• JTSJPPQOZKHHBM-FQEVSTJZSA-N 1-[1-[(2s)-2-amino-3-phenylpropanoyl]piperidin-4-yl]-3,3-dimethylindol-2-one Chemical compound C([C@H](N)C(=O)N1CCC(CC1)N1C(=O)C(C2=CC=CC=C21)(C)C)C1=CC=CC=C1 JTSJPPQOZKHHBM-FQEVSTJZSA-N 0.000 description 1
• YUBDLZGUSSWQSS-UHFFFAOYSA-N 1-benzylpiperidin-4-amine Chemical compound C1CC(N)CCN1CC1=CC=CC=C1 YUBDLZGUSSWQSS-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
• OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
• YOYAIZYFCNQIRF-UHFFFAOYSA-N 2,6-dichlorobenzonitrile Chemical compound ClC1=CC=CC(Cl)=C1C#N YOYAIZYFCNQIRF-UHFFFAOYSA-N 0.000 description 1
• HVHZEKKZMFRULH-UHFFFAOYSA-N 2,6-ditert-butyl-4-methylpyridine Chemical compound CC1=CC(C(C)(C)C)=NC(C(C)(C)C)=C1 HVHZEKKZMFRULH-UHFFFAOYSA-N 0.000 description 1
• KJFJIEHJCVSAKJ-UHFFFAOYSA-N 2-(trimethyl-$l^{5}-phosphanylidene)acetonitrile Chemical compound CP(C)(C)=CC#N KJFJIEHJCVSAKJ-UHFFFAOYSA-N 0.000 description 1
• ZFFBIQMNKOJDJE-UHFFFAOYSA-N 2-bromo-1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(Br)C(=O)C1=CC=CC=C1 ZFFBIQMNKOJDJE-UHFFFAOYSA-N 0.000 description 1
• BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
• WPHUUIODWRNJLO-UHFFFAOYSA-N 2-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=CC=C1S(Cl)(=O)=O WPHUUIODWRNJLO-UHFFFAOYSA-N 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• CSCHRSUHBINSDO-UHFFFAOYSA-N 3,3-dimethyl-1H-indol-2-one hydrochloride Chemical compound Cl.CC1(C)C(=O)Nc2ccccc12 CSCHRSUHBINSDO-UHFFFAOYSA-N 0.000 description 1
• FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
• CQGVHUOEHGTNJQ-RSXGOPAZSA-N 3-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]-1-methyl-1-[(3r)-pyrrolidin-3-yl]urea Chemical compound N([C@@H](CCC=1C=CC=CC=1)C(=O)N1CCC(CC1)N1C2=CC=CC=C2C(C)(C)C1=O)C(=O)N(C)[C@@H]1CCNC1 CQGVHUOEHGTNJQ-RSXGOPAZSA-N 0.000 description 1
• NKMKDPVCESDJCN-UHFFFAOYSA-N 3-[di(propan-2-yl)carbamoylimino]-1,1-di(propan-2-yl)urea Chemical compound CC(C)N(C(C)C)C(=O)N=NC(=O)N(C(C)C)C(C)C NKMKDPVCESDJCN-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical compound C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 description 1
• QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
• 125000006418 4-methylphenylsulfonyl group Chemical group 0.000 description 1
• PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
• WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• 235000019489 Almond oil Nutrition 0.000 description 1
• 125000006847 BOC protecting group Chemical group 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• CWXVXWQQZOZPQQ-SQHAQQRYSA-N C([C@@H](C(=O)N1CCC(CC1)N1C(=O)C(C2=CC=CC=C21)(C)C)NC(=O)NC[C@@H]1NCCCC1)CC1=CC=CC=C1 Chemical compound C([C@@H](C(=O)N1CCC(CC1)N1C(=O)C(C2=CC=CC=C21)(C)C)NC(=O)NC[C@@H]1NCCCC1)CC1=CC=CC=C1 CWXVXWQQZOZPQQ-SQHAQQRYSA-N 0.000 description 1
• DPEUQDWYKBKQLM-LBPRGKRZSA-N CC([C@H](CCc1ccccc1)NC)=O Chemical compound CC([C@H](CCc1ccccc1)NC)=O DPEUQDWYKBKQLM-LBPRGKRZSA-N 0.000 description 1
• GXCZSKGVWGVGPS-JTQLQIEISA-N CC([C@H](Cc1cccc(F)c1)N)=O Chemical compound CC([C@H](Cc1cccc(F)c1)N)=O GXCZSKGVWGVGPS-JTQLQIEISA-N 0.000 description 1
• BSUREVVRQIQMQH-NSHDSACASA-N CC([C@H](Cc1ccccc1C)N)=O Chemical compound CC([C@H](Cc1ccccc1C)N)=O BSUREVVRQIQMQH-NSHDSACASA-N 0.000 description 1
• KVBUDAKYWWHWAI-NSHDSACASA-N CC([C@H](Cc1ccccc1Cl)NC)=O Chemical compound CC([C@H](Cc1ccccc1Cl)NC)=O KVBUDAKYWWHWAI-NSHDSACASA-N 0.000 description 1
• JTSFBXLPWYEDEZ-ZDUSSCGKSA-N CCCN[C@@H](Cc1c(C(F)(F)F)cccc1)C(C)=O Chemical compound CCCN[C@@H](Cc1c(C(F)(F)F)cccc1)C(C)=O JTSFBXLPWYEDEZ-ZDUSSCGKSA-N 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
• VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• 206010051153 Diabetic gastroparesis Diseases 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 208000030814 Eating disease Diseases 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• 206010063655 Erosive oesophagitis Diseases 0.000 description 1
• IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
• 208000019454 Feeding and Eating disease Diseases 0.000 description 1
• 108091006027 G proteins Proteins 0.000 description 1
• 102000030782 GTP binding Human genes 0.000 description 1
• 108091000058 GTP-Binding Proteins 0.000 description 1
• 102000000393 Ghrelin Receptors Human genes 0.000 description 1
• 108010016122 Ghrelin Receptors Proteins 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 206010062767 Hypophysitis Diseases 0.000 description 1
• 206010021333 Ileus paralytic Diseases 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 241001465754 Metazoa Species 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• 208000008589 Obesity Diseases 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 241000350481 Pterogyne nitens Species 0.000 description 1
• 241000872198 Serjania polyphylla Species 0.000 description 1
• 108010052164 Sodium Channels Proteins 0.000 description 1
• 102000018674 Sodium Channels Human genes 0.000 description 1
• UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 206010046543 Urinary incontinence Diseases 0.000 description 1
• 235000010724 Wisteria floribunda Nutrition 0.000 description 1
• 108010084455 Zeocin Proteins 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 239000000205 acacia gum Substances 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
• 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
• 150000008041 alkali metal carbonates Chemical class 0.000 description 1
• 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
• 150000008046 alkali metal hydrides Chemical class 0.000 description 1
• 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
• 125000003282 alkyl amino group Chemical group 0.000 description 1
• 239000008168 almond oil Substances 0.000 description 1
• 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
• 235000008206 alpha-amino acids Nutrition 0.000 description 1
• OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 235000019270 ammonium chloride Nutrition 0.000 description 1
• 239000012491 analyte Substances 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• 238000010420 art technique Methods 0.000 description 1
• 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
• 238000003556 assay Methods 0.000 description 1
• 239000012131 assay buffer Substances 0.000 description 1
• 239000012911 assay medium Substances 0.000 description 1
• 125000005604 azodicarboxylate group Chemical group 0.000 description 1
• WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 1
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
• 150000001576 beta-amino acids Chemical class 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 235000014121 butter Nutrition 0.000 description 1
• 229910000024 caesium carbonate Inorganic materials 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
• 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
• 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 239000003795 chemical substances by application Substances 0.000 description 1
• 230000001713 cholinergic effect Effects 0.000 description 1
• 230000014107 chromosome localization Effects 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 239000013058 crude material Substances 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 229910052805 deuterium Inorganic materials 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 239000012973 diazabicyclooctane Substances 0.000 description 1
• 235000019700 dicalcium phosphate Nutrition 0.000 description 1
• KJOZJSGOIJQCGA-UHFFFAOYSA-N dichloromethane;2,2,2-trifluoroacetic acid Chemical compound ClCCl.OC(=O)C(F)(F)F KJOZJSGOIJQCGA-UHFFFAOYSA-N 0.000 description 1
• IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
• 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 235000014632 disordered eating Nutrition 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 230000008406 drug-drug interaction Effects 0.000 description 1
• 210000001198 duodenum Anatomy 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 238000005868 electrolysis reaction Methods 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940079360 enema for constipation Drugs 0.000 description 1
• 230000003628 erosive effect Effects 0.000 description 1
• 239000003797 essential amino acid Substances 0.000 description 1
• 235000020776 essential amino acid Nutrition 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
• 125000004494 ethyl ester group Chemical group 0.000 description 1
• PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
• 238000001704 evaporation Methods 0.000 description 1
• 230000008020 evaporation Effects 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 230000002964 excitative effect Effects 0.000 description 1
• 239000003925 fat Substances 0.000 description 1
• 235000019197 fats Nutrition 0.000 description 1
• 239000012091 fetal bovine serum Substances 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 238000003818 flash chromatography Methods 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
• 235000019525 fullness Nutrition 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 239000003349 gelling agent Substances 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 125000005842 heteroatom Chemical group 0.000 description 1
• 150000004678 hydrides Chemical class 0.000 description 1
• 238000005984 hydrogenation reaction Methods 0.000 description 1
• 238000007327 hydrogenolysis reaction Methods 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• 210000003016 hypothalamus Anatomy 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 150000002466 imines Chemical class 0.000 description 1
• 150000007975 iminium salts Chemical class 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 239000012535 impurity Substances 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 229910017053 inorganic salt Inorganic materials 0.000 description 1
• 208000028774 intestinal disease Diseases 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 239000003456 ion exchange resin Substances 0.000 description 1
• 229920003303 ion-exchange polymer Polymers 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 239000012948 isocyanate Substances 0.000 description 1
• 150000002513 isocyanates Chemical class 0.000 description 1
• 210000001630 jejunum Anatomy 0.000 description 1
• 150000002576 ketones Chemical class 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 239000010410 layer Substances 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 239000012280 lithium aluminium hydride Substances 0.000 description 1
• AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical compound [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 1
• YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
• XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
• 229910052808 lithium carbonate Inorganic materials 0.000 description 1
• 229910000103 lithium hydride Inorganic materials 0.000 description 1
• 229910000032 lithium hydrogen carbonate Inorganic materials 0.000 description 1
• GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
• 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
• HQRPHMAXFVUBJX-UHFFFAOYSA-M lithium;hydrogen carbonate Chemical compound [Li+].OC([O-])=O HQRPHMAXFVUBJX-UHFFFAOYSA-M 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 239000003589 local anesthetic agent Substances 0.000 description 1
• 210000000111 lower esophageal sphincter Anatomy 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 150000002678 macrocyclic compounds Chemical class 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
• MFJZZRBJASNGAJ-UHFFFAOYSA-N methyl 2-(2-bromo-5-fluorophenyl)-2-methylpropanoate Chemical compound COC(=O)C(C)(C)C1=CC(F)=CC=C1Br MFJZZRBJASNGAJ-UHFFFAOYSA-N 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 230000001617 migratory effect Effects 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 125000002757 morpholinyl group Chemical group 0.000 description 1
• 230000004899 motility Effects 0.000 description 1
• 230000004118 muscle contraction Effects 0.000 description 1
• DOYQCFKQLCEETJ-VWLOTQADSA-N n-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-3-phenylpropan-2-yl]piperidine-4-carboxamide Chemical compound C([C@@H](C(=O)N1CCC(CC1)N1C(=O)C(C2=CC=CC=C21)(C)C)NC(=O)C1CCNCC1)C1=CC=CC=C1 DOYQCFKQLCEETJ-VWLOTQADSA-N 0.000 description 1
• PADXATLUTACXAZ-VWLOTQADSA-N n-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-3-(2-fluorophenyl)-1-oxopropan-2-yl]piperidine-4-carboxamide Chemical compound C([C@@H](C(=O)N1CCC(CC1)N1C(=O)C(C2=CC=CC=C21)(C)C)NC(=O)C1CCNCC1)C1=CC=CC=C1F PADXATLUTACXAZ-VWLOTQADSA-N 0.000 description 1
• NSRZAOPRDPEUHS-VWLOTQADSA-N n-[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-3-(3-fluorophenyl)-1-oxopropan-2-yl]piperidine-4-carboxamide Chemical compound C([C@@H](C(=O)N1CCC(CC1)N1C(=O)C(C2=CC=CC=C21)(C)C)NC(=O)C1CCNCC1)C1=CC=CC(F)=C1 NSRZAOPRDPEUHS-VWLOTQADSA-N 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 201000001119 neuropathy Diseases 0.000 description 1
• 230000007823 neuropathy Effects 0.000 description 1
• 229910052759 nickel Inorganic materials 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• 239000012299 nitrogen atmosphere Substances 0.000 description 1
• 239000002687 nonaqueous vehicle Substances 0.000 description 1
• 239000012038 nucleophile Substances 0.000 description 1
• 238000005935 nucleophilic addition reaction Methods 0.000 description 1
• 230000000269 nucleophilic effect Effects 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 235000020824 obesity Nutrition 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 239000012074 organic phase Substances 0.000 description 1
• 150000002924 oxiranes Chemical class 0.000 description 1
• NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
• YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
• NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
• 201000007620 paralytic ileus Diseases 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 208000033808 peripheral neuropathy Diseases 0.000 description 1
• 239000003208 petroleum Substances 0.000 description 1
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
• 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
• CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
• 235000021317 phosphate Nutrition 0.000 description 1
• WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 239000011574 phosphorus Substances 0.000 description 1
• 238000006303 photolysis reaction Methods 0.000 description 1
• 230000015843 photosynthesis, light reaction Effects 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 1
• 125000003386 piperidinyl group Chemical group 0.000 description 1
• 230000001817 pituitary effect Effects 0.000 description 1
• 210000003635 pituitary gland Anatomy 0.000 description 1
• 229910052697 platinum Inorganic materials 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229960003975 potassium Drugs 0.000 description 1
• IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
• NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
• 229910000105 potassium hydride Inorganic materials 0.000 description 1
• LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
• ZMJJCODMIXQWCQ-UHFFFAOYSA-N potassium;di(propan-2-yl)azanide Chemical compound [K+].CC(C)[N-]C(C)C ZMJJCODMIXQWCQ-UHFFFAOYSA-N 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
• 230000001141 propulsive effect Effects 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
• 235000018102 proteins Nutrition 0.000 description 1
• 102000004169 proteins and genes Human genes 0.000 description 1
• 108090000623 proteins and genes Proteins 0.000 description 1
• KOUKXHPPRFNWPP-UHFFFAOYSA-N pyrazine-2,5-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CN=C(C(O)=O)C=N1 KOUKXHPPRFNWPP-UHFFFAOYSA-N 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 238000010791 quenching Methods 0.000 description 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 230000035484 reaction time Effects 0.000 description 1
• 229940044551 receptor antagonist Drugs 0.000 description 1
• 239000002464 receptor antagonist Substances 0.000 description 1
• 238000005932 reductive alkylation reaction Methods 0.000 description 1
• 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
• 230000036186 satiety Effects 0.000 description 1
• 235000019627 satiety Nutrition 0.000 description 1
• 239000012047 saturated solution Substances 0.000 description 1
• 238000007789 sealing Methods 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 239000000741 silica gel Substances 0.000 description 1
• ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
• QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
• 229940054269 sodium pyruvate Drugs 0.000 description 1
• 229940079832 sodium starch glycolate Drugs 0.000 description 1
• 239000008109 sodium starch glycolate Substances 0.000 description 1
• 229920003109 sodium starch glycolate Polymers 0.000 description 1
• YHOBGCSGTGDMLF-UHFFFAOYSA-N sodium;di(propan-2-yl)azanide Chemical compound [Na+].CC(C)[N-]C(C)C YHOBGCSGTGDMLF-UHFFFAOYSA-N 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 235000010356 sorbitol Nutrition 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 125000000547 substituted alkyl group Chemical group 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 229960002317 succinimide Drugs 0.000 description 1
• 230000006103 sulfonylation Effects 0.000 description 1
• 238000005694 sulfonylation reaction Methods 0.000 description 1
• 229910052717 sulfur Chemical group 0.000 description 1
• 239000011593 sulfur Chemical group 0.000 description 1
• YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
• 239000002511 suppository base Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 238000001308 synthesis method Methods 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 239000002278 tabletting lubricant Substances 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• ZGKHEBZOPGGEPY-UHSQPCAPSA-N tert-butyl (3r)-3-[[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamoyl]piperidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC[C@H]1C(=O)N[C@H](C(=O)N1CCC(CC1)N1C2=CC=CC=C2C(C)(C)C1=O)CCC1=CC=CC=C1 ZGKHEBZOPGGEPY-UHSQPCAPSA-N 0.000 description 1
• AKQXKEBCONUWCL-MRVPVSSYSA-N tert-butyl (3r)-3-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H](N)C1 AKQXKEBCONUWCL-MRVPVSSYSA-N 0.000 description 1
• DMBKWEHXTOCLTC-UHFFFAOYSA-N tert-butyl 4-amino-4-methylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C)(N)CC1 DMBKWEHXTOCLTC-UHFFFAOYSA-N 0.000 description 1
• LMGPWGGAZSFLPG-DEOSSOPVSA-N tert-butyl n-[(2s)-1-[4-(5-fluoro-3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C([C@H](NC(=O)OC(C)(C)C)C(=O)N1CCC(CC1)N1C2=CC=C(F)C=C2C(C)(C)C1=O)CC1=CC=CC=C1 LMGPWGGAZSFLPG-DEOSSOPVSA-N 0.000 description 1
• MRDMCHRKABBZIY-YTMVLYRLSA-N tert-butyl n-[(3s)-1-[[(2s)-1-[4-(3,3-dimethyl-2-oxoindol-1-yl)piperidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamoyl]pyrrolidin-3-yl]-n-methylcarbamate Chemical compound C1[C@@H](N(C)C(=O)OC(C)(C)C)CCN1C(=O)N[C@H](C(=O)N1CCC(CC1)N1C2=CC=CC=C2C(C)(C)C1=O)CCC1=CC=CC=C1 MRDMCHRKABBZIY-YTMVLYRLSA-N 0.000 description 1
• 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 238000012360 testing method Methods 0.000 description 1
• CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
• WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
• 230000001225 therapeutic effect Effects 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 150000007970 thio esters Chemical class 0.000 description 1
• 210000001519 tissue Anatomy 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 238000009827 uniform distribution Methods 0.000 description 1
• 210000003932 urinary bladder Anatomy 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 238000002424 x-ray crystallography Methods 0.000 description 1
• UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 1